Diagnostics Pipeline: FDA Opens Path for Blood Tests Assessing Genetic Cancer Risk
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article